Sorafenib, an oral multikinase inhibitor that blocks the Ras/Raf/MEK/ERK signaling axis by inhibiting Raf kinase activity,1, 2 is the first clinically approved target therapy for advanced hepatocellular carcinoma (HCC) patients.2, 3. Here, MAP2K7 is linked to hepatocellular carcinoma.